Background: Improvement in 6 minute walk distance (6MWD) after 12-16 weeks of treatment has been used as the primary end point in many pivotal pulmonary arterial hypertension (PAH) clinical trials. However, the consensus view is that although baseline 6MWD predicts survival, change in 6MWD ( 6MWD) does not. Aim: To determine whether 6MWD after 3 months of disease targeted therapy predicts long term survival in patients from the Pulmonary Hypertension Registry of the UK and Ireland. Methods: Retrospective observational study of all incident cases of idiopathic (IPAH), heritable and anorexigen-associated PAH diagnosed in the UK and Ireland between 1st January 2001 and 31st December 2009. Patients were divided into low and high baseline 6MWD by the median 6MWD (295 m). Results: Total of 646 patients were diagnosed. After 3 months of disease targeted therapy, patients with absolute 6MWD >353 m (corresponding to the median value at 3 months) had better survival than those with 6MWD < 353 m. Mean improvement in 6MWD after 3 months of therapy was 42.4±75.8 m (median 37.5 m). Patients with greater increase in 6MWD from baseline to 3 months had better post-3 months survival (hazard ratio 0.65, 95% confidence interval 0.42 to 0.99 per 100 metres improvement). In patients with low baseline 6MWD, 6MWD at 3 months of > 37.5 m had better survival compared to those with 6MWD at 3 months of < 37.5 m (Log-rank, p=0.03). This is not seen in patients with high baseline 6MWD. Conclusion: Change in 6MWD after 3 months of treatment predicts long term survival in patients with low baseline 6MWD. Rationale: Acute vasodilator testing with iNO during right heart catheterization in pulmonary arterial hypertension predicts suvival and response to calcium channel blockers. iEPO is less expensive than iNO with fewer systemic effects than intravenous EPO. We hypothesized that iEPO has similar vasodilatory efficacy as iNO and their combination has additive effects. Methods: Prospective double-blinded study of PH treatment-naïve consecutive patients. Patients >18 years, WHO Group1-5 with pulmonary capillary wedge pressures ≤ 20 were included. Patients received iNO, iEPO and their combination in random order, with a washout phase between treatments. Hemodynamics at baseline and treatments were reported as%change, means±SD. Correlation was assessed with regression analysis. p<0.05 was significant. Results: Patients enrolled: Group 1 (11), Group 2 (9), Group 3 (1), Group 4 (1), Group 5 (1). 2 did not complete the study (hypoxemia and dyspnea respectively). Mean pulmonary artery pressures (mPAP) in Groups 1, 2 and other groups were 47±12, 35±7 and 35±9.2. Mean pulmonary vascular resistances (PVR) were Background: In Pulmonary Hypertension (PH) the Pulmonary Artery (PA) dilates proportionally with pulmonary artery mean pressure (PAPx) and resistance (PVR) together with a reduced pulsatility. Aim of the study: Our aim was to assess effect of vasodilator therapy (eg Bosentan) upon diameter and pulsatility of PA during PH. Methods: Twenty patients affected by PH were studied by means of whole body pletismography, haemodynamics, and HRCT. Bosentan (125mg bid) was administered for two years and examination were repeated again on 10 patients still alive.
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Comparison of hemodynamic effects of inhaled nitric oxide (iNO) and inhaled epoprostenol (iEPO) in patients with pulmonary hypertension (PH)
Shilpa A. DeSouza, Kristen D. Sagliani, Ioana R. Preston, Kari E. Roberts, Archan Shah, Nicholas S. Hill. Pulmonary, Ctitical Care and Sleep Medicine, Tufts Medical Center, Boston, MA, United States Rationale: Acute vasodilator testing with iNO during right heart catheterization in pulmonary arterial hypertension predicts suvival and response to calcium channel blockers. iEPO is less expensive than iNO with fewer systemic effects than intravenous EPO. We hypothesized that iEPO has similar vasodilatory efficacy as iNO and their combination has additive effects. Methods: Prospective double-blinded study of PH treatment-naïve consecutive patients. Patients >18 years, WHO Group1-5 with pulmonary capillary wedge pressures ≤ 20 were included. Patients received iNO, iEPO and their combination in random order, with a washout phase between treatments. Hemodynamics at baseline and treatments were reported as%change, means±SD. Correlation was assessed with regression analysis. p<0.05 was significant. Results: Patients enrolled: Group 1 (11), Group 2 (9), Group 3 (1), Group 4 (1), Group 5 (1). 2 did not complete the study (hypoxemia and dyspnea respectively). Mean pulmonary artery pressures (mPAP) in Groups 1, 2 and other groups were 47±12, 35±7 and 35±9.2. Mean pulmonary vascular resistances (PVR) were Mean (SD) iNO 20PPM iEPO 50mcg/kg/min R 2 p value Group 1 % mPAP -11.9(6.6) -11. 
Introduction:
Patients who have mitral valve (MV) disease with associated pulmonary hypertension (PH) may develop acute rises in pulmonary vascular resistance (PVR) perioperatively.Such pulmonary hypertensive crises may significantly increase perioperative morbidity and mortality. Although there is limited experience with agents to reduce the PVR, their use may be associated with systemic hypotension. Aim: To evaluate the safety and haemodynamic effects of intravenous (IV) sildenafil perioperatively, in patients with PH and MV disease undergoing cardiac surgery. Method: Nine patients, two males and seven females, age range 64 to 81 (median 76) years, with PH, mean pulmonary artery pressure range 30 to 56 (median 43) mmHg, associated with MV disease, who had MV surgery, received IV sildenafil (1mg/ml) at a rate of 1mg/kg for one hour in the immediate post operative period.Pulmonary and systemic haemodynamic measurements were recorded at ten-minute intervals. Results: A statistically significant reduction (p=0.006) in PVR was observed.There was a trend towards improvement in the cardiac index (CI), although it did not reach statistical significance (p=0.059).Mean systemic arterial pressure remained stable and no detrimental effect on other haemodynamic parameters was noted. Discussion: Our study suggests that perioperative use of IV sildenafil is safe and not associated with systemic hypotension.We observed a favourable response in PVR and a trend towards improvement in CI.We suggest that IV sildenafil should be considered for selected patients with MV disease and PH who require MV surgery. The management of pulmonary arterial hypertension (PAH) has evolved since the early 2000s with the introduction of oral therapies, and consequently data on the current use of epoprostenol (epo) are scarce.
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Methods: Patients (pts) with a newly diagnosed PH treated with epo were analysed from the prospective French PH Registry launched in Nov. 2006. The cut-off date was 1 Sept. 2010. Results: 177 adult pts were identified for analysis. 127 (72%) had PAH (group 1) and among them, 81 (64%) had idiopathic, heritable or anorexigen-associated PAH (IHAr-PAH), 17 (13%) connective tissue disease and 17 (13%) portopulmonary hypertension. 6% of patients received epo for pulmonary veno-occlusive disease, 8% for PH with lung diseases, 12% for chronic thromboembolic PH and 2% for miscellaneous PH. At the time of epo initiation, mean (±SD) age was 51±17 yrs. 7%, 43% and 50% of pts were in NYHA class II, III, IV, respectively, and 47% were naive to PAH specific therapy. The 6-min walk distance was 309±131 m. Haemodynamic measures confirmed severe impairment with mean PAP 56±13 mmHg, right atrial pressure 10±6 mmHg, cardiac index 2.0±0.6 L/min/m 2 and pulmonary vascular resistance 1194±571 dyn s cm -5 . In the overall PH population, survival estimates following epo commencement were 77%, 63% and 54% at 1, 2 and 3 years, respectively, and 82%, 72% and 69% in the subgroup of pts with IHAr-PAH. Conclusion: Epo is still used as first-line therapy in severe forms of PAH. It is notably prescribed in non-group 1 PH in 28% of cases. In incident pts with IHAr-PAH, 1-and 2-year survival is similar to that of historical cohorts, despite the prior use of an oral treatment in 48% percent of them.
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Effectiveness of "Korargin" in the therapy of pulmonary arterial hypertension in patients with systemic lupus erythematosus Olga Yakovleva, Aleksandra Klekot. Clinical Pharmacy and Clinical Pharmacology, Vinnitsa National Medical University, Vinnitsa, Ukraine Introduction: Pulmonary arterial hypertension (PAH) in systemic lupus erythematosus (SLE) is a complex therapeutic problem and occurs from 5 to 14%. The main pathophisiological mechanism of PAH is an endothelium dysfunction with abnormality of nitric oxide synthesis (Ghofrani H.A. et al. J. Am. Coll. Cardiol. 2004; 43; 68S-72S) . Objective was to examine the efficacy of the "Korargin" (1 tabl. contains 0.1g L-arginine and 0.1g inosine), production of "Korargin", Uman, Ukraine in SLE patients with PAH. Methods: 30 SLE patients with PAH (mean age is 48.3±1.7 y.)were studied, whom to conventional therapy was added "Korargin" 2 tablets 3 times a day for 8 weeks. The object of the effectiveness were increased distance of 6-minute walk (6MW), changes in pulmonary artery pressure and improvement of functional class (FC) PAH on WHO. Results: II FC PAH was diagnosed in 80% patients. Patients with III FC was 20%. From the 4th week and untill the end of the initial study, the patients demonstrated a significant increase in the distance test of 6MW an average of 61.2±3.2 m compared with the baseline data. In addition, it was observed decrease in pulmonary arterial pressure on 11% in 37% of patients. 64% patients improved their FC. Conclusion: Despite of the fact, that insufficient long-term follow-up period and relatively non-severe population of SLE patients with PAH, having taken "Korargin", patients has improved tolerance to phisical activity, FC PAH on WHO and hemodynamic parameters. Introduction: The Registry to EValuate Early And Long-term PAH Disease Management (REVEAL), a 55-center observational, US-based study, describes current demographic, clinical, and treatment patterns in PAH patients (pts). Objective: Determine if pts who improve from functional class (FC) III at enrollment to FC I/II at follow-up (f/u) have a better 2-year survival than pts who remain FC III. Methods: 1,082 adults enrolled in REVEAL were assessed as FC III at enrollment (based on most recent pre-enrollment evaluation) and had ≥1 f/u FC assessment within the first year after enrollment. We classified pts based on their first FC f/u assessment after enrollment as: 1) improved if FC improved to FC I/II; 2) unchanged if remained FC III; or 3) deteriorated if worsened to FC IV. We compared survival (estimates±SE) of these 3 subgroups from the first f/u FC assessment (log-rank test). Results: FC improved in 26% (n=281) of pts, was unchanged in 66% (n=718) and deteriorated in 8% (n=83). At enrollment, there were no differences in gender, PAH subgroup, right atrial pressure, or cardiac index; significant differences were observed in age, proportion of newly diagnosed (diagnostic confirmatory cardiac catheterization ≤3 months before enrollment) pts, and 6-minute walk distance among groups. Two-year survival was 88±2%, 76±2%, and 34±6% for FC I/II, FC III, and FC IV pts, respectively (P<0.001 for all pairwise comparisons). Results are similar for both newly and previously diagnosed pts who were FC III at enrollment. The treatment of patients with Parenchymal Lung Disease (PLD) and Pulmonary Hypertension (PH) is challenging. PLD is characterized by an imbalance between alveolar ventilation and pulmonary blood flow. The ability to deliver therapy to areas of lung that are well ventilated would utilize preserved V/Q matching and improve drug delivery. This would reduce undesirable alterations in perfusion caused by a systemic vasodilator and provide a more effective way of treating these patients. We examined the response of patients with PLD and PH receiving Inhaled Treprostinil. We followed eight patients with NYHA Functional Class IIIB to IV symptoms with a mean PAP >25mmHg and PCWP of <15mmHg for at least 3-months. Five subjects had Obstructive Lung Disease and three were classified as having Restrictive Lung Disease. All followed the usual protocol starting with three breaths four times a day and gradually increased to the goal of nine breaths a day. Two patients had to be reduced to six breaths a day due to throat irritation but were able to increase back to nine breaths a day. One patient stopped the Inhaled Treprostinil one week after starting therapy for worsening symptoms of shortness of breath. Two patients were on a background PDE5 Inhibitor prior to starting the inhaled treatment. All but one patient reported less shortness of breath after initiation of treatment. The majority of patients had an improvement in 6-MWD and Borg Dyspnea Scale. Our experience suggests that patients with PLD and PH can be safely treated with inhaled Treprostinil. Inhaled Treprostinil may offer an effective and well tolerated treatment in subjects with PLD and shortness of breath exacerbated by PH. Introduction: Cardiotonic agents play a major role in the therapy of heart failure. Apart from their effects on ventricular contractility and systemic afterload, they may affect the tone of pulmonary arteries (PAs) and pulmonary veins (PVs). However, in particular the responses of PVs to cardiotonic agents are only poorly defined.
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Aims and objectives:
We investigated the effects of α-and β-adrenergic agents as well as vasopressin in PAs and PVs to clarify their potential role in pulmonary hypertension (PH) or lung edema and coexisting heart failure. Methods: After terminal anaesthesia with pentobarbital, PCLS were prepared from female Dunken Hartley guinea pigs and investigated by video microscopy. Concentration-response curves of various cardiotonic drugs were analyzed in PAs and PVs. Results: After stimulation with α1-adrenergic agents, PAs contracted up to 80.5% ± 3, in respect to the initial vessel area, whereas β2-adrenergic agents showed only little effect. In contrast, after stimulation of α1-receptors PVs contracted up to 77% ± 2.6 and relaxed due to activation of β2-receptors up to 124.7% ± 2.8. Notably, inhibition of β2-receptors unmasked the α1-mimetic effect of (nor)epinephrine. Vasopressin contracted PVs up to 76.4% ± 7.4, without any effect on PAs. Conclusion: Thus, vasoconstriction of PVs enhances capillary and venous hydrostatic pressures and promotes the development of lung edema. Our findings suggest that (nor)epinephrine in combination with unselective β-blockers and vasopressin might be harmful in patients with left heart failure. Further, α1-mimetic agents might exacerbate a pre-existing PH and a failing right ventricle by contracting PAs, whereas vasopressin might not. Microbial activity and stability of epoprostenol with expanded stability (EPO-ES, Veletri ® ) were investigated at 5°C and 25°C over a range of concentrations. EPO-ES was reconstituted and immediately diluted with sterile Water for Injection (WFI) or Sodium Chloride 0.9% Injection (NaCl). Stability for up to 72 hours (h) at 25°C was measured immediately following dilution (A), and after 1 (B) or 7 days (C) storage at 5°C. Shelf-life was assessed by determining the time over which potency ≥90% was maintained. For microbiological testing, diluted samples of EPO-ES were inoculated with S. aureus, P. aeruginosa, E. coli, C. albicans, A. niger or C. sporogenes and incubated for up to 14 days at 5°C or 4 days at 25°C. Potency of EPO-ES 6,000 ng/mL at 12h under test condition B was 92% for both diluents. Potency of EPO-ES 9,000 ng/mL under test condition C was 91% for WFI and 87% for NaCl at 12h, and ≥90% for both diluents at 12 and 24 h at 12,000 431s Conclusions: Nitrous oxide rebreathing CO measurement can be used as a monitioring tool of disease monitoring and potentially reduce the need for invasive CO measurement in patients with pulmonary hypertension.
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Use of non invasive gas exchange to track pulmonary vascular responses to exercise in heart failure Paul Woods, Bryan Taylor, Thomas Olson, Bruce Johnson.
Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, United States
Simple metrics to quantify severity of pulmonary hypertension (PH) are lacking, particularly with exercise. Studies have suggested that end tidal CO 2 (PetCO 2 ) and ventilatory efficiency (V E /VCO 2 ) may be good indicators of the pulmonary vascular (PV) response to exercise in patients with PH. In addition, measures of PV capacitance (stroke volume/pulmonary arterial pressure, Pv CAP ) are predictive of survival in the PH population and may potentially be estimated with gas exchange. PH is common in heart failure (HF) and appears to have both passive and reactive components. However, HF is associated with a number of gas exchange abnormalities that could limit the ability of using PetCO 2 or V E /VCO 2 to estimate the presence of PH. The focus of this study was, a) determine how well non-invasive gas exchange tracks the PV response to exercise and b) test a noninvasive estimate of Pv CAP . Forty-two patients with HF (age 54±9, LVEF 20±6, NYHA class 3±1) undergoing rt.-hrt catheterization as part of a pre-transplant evaluation were studied. PV pressures (Ppa/Ppw), cardiac output and PV resistance (PVR) were obtained with simultaneous measures of gas exchange. PetCO 2 and V E /VCO 2 obtained during moderate exercise (VO 2 9±2ml/kg/mn, 37±13W) were highly correlated (r -0.95) and thus data were analyzed in tertiles according to PetCO 2 (mean 23±3, 29±2, 36±4mmHg). PVR followed a decreasing trend from low to high PetCO 2 groups (365±256, 282±162, 188±91WU, p<0.01, r-0.47). Pv CAP from catheter measures was highly associated with a value estimated from O 2 pulse/(1/PetCO 2 ), (r=0.84). Non invasive gas exchange measures may represent a relatively simple way to track PV response to exercise in HF. NIH HL71478. Background: Flight-related complications reported in individuals with pulmonary arteriovenous malformations (PAVMs) and hereditary haemorrhagic telangiectasia (HHT) have included deep venous thrombosis (DVT), ischaemic stroke, and haemorrhage from PAVMs. In addition there are concerns that the reduced barometric pressure associated with flying might exacerbate PAVM-induced hypoxaemia. Methods: With ethical approval (NRES 10/H0806/8), individuals with PAVMs and/or HHT were sent a questionnaire to document flights they had taken, and symptoms experienced during or shortly afterwards. Responses were correlated with sea level erect oxygen saturations (SaO 2 ), and haemoglobin (Hb). Results: 159 replies were received (response rate 52%). 147 individuals had flown, 97 (66%) with PAVMs. The median number of flights per individual was 25, totalling 18,943 flight hours in 3,950 flights. 111 (77%) respondents reported no complications. Six (4%) reported dyspnoea, two (1%) had a deep vein thrombosis, and one had an ischaemic stroke whilst flying. However the most common in-flight complications were HHT-related nosebleeds, reported by 26 (18% Background: Endothelin receptor antagonists are used for treatment of pulmonary arterial hypertension (PAH). However, these drugs have been associated with liver injury and patients require regular monitoring of liver function (LFT). We introduced a postal system whereby patients receiving these therapies had blood taken by their local practitioner and sent pre packaged boxes to our centre for analysis and monitoring on a monthly basis. 
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